Li P, Fu L, Liao Z, Peng Y, Ning C, Gao C, et al
This challenge was realized using duodenocutaneous fistulas in rats and the parallel therapy, likely related to nitric oxide (NO)-system, the stable pentadecapeptide BPC 157, (4-9) (an anti-ulcer peptide supposed to be novel mediator of Roberts cytoprotection (as stable in human gastric juice more than 24 hours)) (4-9), known to heal fistulas (10-12) and skin wounds (13-15), the nitric-oxide synthase (NOS)-substrate L-arginine and/or the NOS-inhibitor L-nitro-arginine methyl ester (L-NAME)
doi: 10.1016/j.molcel.2018.11.028 140 Mahoney-SanchezLBouchaouiHBoussaadIJonneauxATimmermanKBerdeauxOet al
#TheMedicineBox | Dr
Important Safety Information Do not use AOD-9604 if you: Have active cancer or malignancy (use only under medical supervision with appropriate monitoring) Are pregnant or breastfeeding (safety data lacking in these populations) Have known allergy to growth hormone fragments or peptide compounds Have severe uncontrolled metabolic or cardiovascular disease without medical supervision Common side effects may include: Injection site reactions (mild redness, swelling, or tenderness), occasional mild headaches during initial use, and transient lightheadedness
